ESCC is the 6th leading cause of cancer-related mortality worldwide3–5,44 and the dismal outlook of this disease has led us to investigate the putative tumor-promoting role of GSK3β as a new therapeutic target in ESCC. This evidence concerns the gene GSK3B and esophageal squamous cell carcinoma.